To investigate whether targeted blockade of CD8 antagonizes or abrogates the therapeutic effects of EZM2302, we treated 4T1.2 tumors with EZM2302 alone, or in combination with an anti-CD8 mAb, followed by measuring survival, tumor growth, metastasis, and CD8+ T cell infiltration. The gene discussed is CD8A; the disease is neoplasm.